# PRESERVE-006 (NCT05682443)

> ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05682443
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: OncoC4, Inc.
- Conditions: Metastatic Castration-resistant Prostate Cancer
- Interventions: ONC-392 low; ONC-392 high; lutetium Lu 177 vipivotide tetraxetan
- Enrollment: 148
- Primary outcome: DLT (Dose escalation Phase 1)
- Primary outcome: PSA50 (Dose Expansion Phase 2)
- Primary outcome: rPFS (Dose Expansion Phase 2)
- Primary outcome: TEAEs and irAEs (Dose Expansion Phase 2)

## Indexed commentary on PRESERVE-006 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=preserve-006-nct05682443